We are thrilled to announce major momentum in our pipeline, driven by our proprietary Natural Drug Delivery Platform.
In oncology, we have successfully completed a Pre-IND meeting with the U.S. FDA for SBI-101, our novel candidate targeting PD-1 blockade resistant Cold Tumors. This marks a crucial step forward in addressing a major unmet need for cancer treatment.
Simultaneously, we are accelerating another program (SBI-102) toward clinical entry in Australia. We have partnered with a leading global CRO for our NNP-based candidate for inflammatory and autoimmune diseases. Building on its existing Orphan Drug Designation (ODD) from the FDA, our immediate next step is to submit our clinical trial application to the TGA.
These parallel advancements highlight the immense potential of our NNP platform to tackle challenging diseases. We are more committed than ever to progressing our therapies for patients around the globe!
For more details, please refer to below links
SBI-101: https://www.sciencedirect.com/science/article/pii/S016836592200637X
SBI-102: https://www.nature.com/articles/s41467-025-57133-w
We are thrilled to announce major momentum in our pipeline, driven by our proprietary Natural Drug Delivery Platform.
In oncology, we have successfully completed a Pre-IND meeting with the U.S. FDA for SBI-101, our novel candidate targeting PD-1 blockade resistant Cold Tumors. This marks a crucial step forward in addressing a major unmet need for cancer treatment.
Simultaneously, we are accelerating another program (SBI-102) toward clinical entry in Australia. We have partnered with a leading global CRO for our NNP-based candidate for inflammatory and autoimmune diseases. Building on its existing Orphan Drug Designation (ODD) from the FDA, our immediate next step is to submit our clinical trial application to the TGA.
These parallel advancements highlight the immense potential of our NNP platform to tackle challenging diseases. We are more committed than ever to progressing our therapies for patients around the globe!
For more details, please refer to below links
SBI-101: https://www.sciencedirect.com/science/article/pii/S016836592200637X
SBI-102: https://www.nature.com/articles/s41467-025-57133-w